Download PDF
Endoskopie heute 2004; 17(2): 104-111
DOI: 10.1055/s-2004-822709
Originalarbeit

© Georg Thieme Verlag Stuttgart · New York

Kolonkarzinom: Palliative und adjuvante Chemotherapie

Colon Cancer: Palliative and Adjuvant ChemotherapyV. Kächele1 , G. Adler1 , T. Seufferlein1
  • 1Abt. Innere Medizin I, Universitätsklinik Ulm
Further Information

Publication History

Publication Date:
06 July 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Bei beiden Geschlechtern stellt das kolorektale Karzinom die zweithäufigste Todesursache dar und trägt erheblich zur Mortalität unter den Tumorerkrankungen bei. Während bis vor kurzem die adjuvante und palliative Chemotherapie des metastasierten kolorektalen Karzinoms im Wesentlichen aus 5-Fluoruracil bestand, konnten in den letzten Jahren durch die Einführung von Irinotecan und Oxaliplatin und in jüngster Zeit durch die so genannten „targeted therapies” entscheidende Verbesserungen im Tumoransprechen erzielt werden. Dies führte auch zu einer signifikanten Verlängerung des Überlebens der Patienten mit metastasierten kolorektalen Karzinomen bei akzeptabler Toxizität. Für einige dieser Patienten kommen durch ein sehr effektives Downstaging von Lebermetastasen sogar wieder chirurgische Verfahren mit kurativer Intention in Betracht. In dieser Übersicht werden die für die adjuvante und palliative Therapie validierten Therapieschemata dargestellt.

Abstract

Colorectal is a major cause of cancer death in the western world. Until recently, 5-FU was the most commonly used chemotherapy for the adjuvant as well as palliative treatment of colorectal cancer. The introduction of irinotecan and oxaliplatin and most recently of the so called “targeted therapies” into the therapeutic alogorithm of colorectal cancer significantly improved response rates and survival of patients. At the same time, toxicity of these therapies is acceptable. Due to efficient downstaging of liver metastases in reponse to the novel therapeutic strategies some patients become even eligible for surgical procedures. In this review we will highlight the novel strategies for the adjuvant and palliative treatment of colorectal cancer.

Schlüsselwörter

Kolonkarzinom - adjuvante und palliative Chemotherapie

Key words

Colon cancer - adjuvant and palliative chemotherapy

Literatur

  • 1 Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland .Krebs in Deutschland - Häufigkeiten und Trends. 3. erweiterte, aktualisierte Auflage. Saarbrücken 2002; 28-31
    Google Scholar
  • 2 Nordlinger B, Guiguet M, Vaillant J C. et al . Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1 568 patients. Association Francaise de Chirurgie.  Cancer. 1996;  77 1254-1262
    CrossrefPubMedGoogle Scholar
  • 3 Moertel C G, Fleming T R, Macdonald J S. et al . Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.  Ann Intern Med. 1995;  122 321-326
    CrossrefPubMedGoogle Scholar
  • 4 Douillard J Y, Cunningham D, Roth A D. et al . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.  Lancet. 2000;  355 1041-1047
    CrossrefPubMedGoogle Scholar
  • 5 Saltz L B, Cox J V, Blanke C. et al . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2000;  343 905-914
    CrossrefPubMedGoogle Scholar
  • 6 de Gramont A, Figer A, Seymour M. et al . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.  J Clin Oncol. 2000;  18 2938-2947
    CrossrefPubMedGoogle Scholar
  • 7 Giacchetti S, Perpoint B, Zidani R. et al . Phase-III-multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.  J Clin Oncol. 2000;  18 136-147
    PubMedGoogle Scholar
  • 8 Tournigand C, André T, Achille E. et al . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study.  J Clin Oncol. 2004;  22 229-237
    CrossrefPubMedGoogle Scholar
  • 9 Goldberg R M, Sargent D J, Morton R F. et al . A randomized controlled trial of fluorouracil plus Leucovorin, Irinotecan, and Oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.  J Clin Oncol. 2004;  22 23-30
    CrossrefPubMedGoogle Scholar
  • 10 Scheithauer W, Rosen H, Kornek G V, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.  British Med J. 1993;  306 752-755
    CrossrefPubMedGoogle Scholar
  • 11 Nordic Gastrointestinal Tumor Adjuvant Therapy Group . Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial.  J Clin Oncol. 1992;  10 904-911
    CrossrefPubMedGoogle Scholar
  • 12 Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden P O,. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group . Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer.  Cancer. 1994;  73 556-562
    PubMedGoogle Scholar
  • 13 Simmonds P C,. Colorectal Cancer Collaborative Group . Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis.  British Med J. 2000;  321 531-535
    CrossrefPubMedGoogle Scholar
  • 14 Advanced Colorectal Cancer Meta-Analysis Project . Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate.  J Clin Oncol. 1992;  10 896-903
    PubMedGoogle Scholar
  • 15 Ardalan B, Chua L, Tian E M. et al . A phase-II-study of weekly 24 hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma.  J Clin Oncol. 1991;  9 625-630
    PubMedGoogle Scholar
  • 16 Lokich J J, Ahlgren J D, Gullo J J. et al . A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.  J Clin Oncol. 1989;  7 425-432
    PubMedGoogle Scholar
  • 17 Meta-analysis Group in Cancer . Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors.  J Clin Oncol. 1998;  16 3537-3541
    PubMedGoogle Scholar
  • 18 Köhne C H, Wils J, Lorenz M. et al . Randomized phase-III-study of high-dose Fluorouracil given as a weekly 24 hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer.  J Clin Oncol. 2003;  21 3721-3728
    CrossrefPubMedGoogle Scholar
  • 19 Van Cutsem E, Twelves C, Cassidy J. et al . Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase-III-study.  J Clin Oncol. 2001;  19 4097-4106
    PubMedGoogle Scholar
  • 20 Hoff P M, Ansari R, Batist G. et al . Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase-III-study.  J Clin Oncol. 2001;  19 2282-2292
    PubMedGoogle Scholar
  • 21 Cassidy J, Twelves C, Van Cutsem E. et al . First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.  Ann Oncol. 2002;  13 566-575
    CrossrefPubMedGoogle Scholar
  • 22 Köhne C H, Cunningham D, Di Constanzo F. et al . Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3 825 patients.  Ann Oncol. 2002;  13 308-317
    CrossrefPubMedGoogle Scholar
  • 23 Vanhöfer U, Köhne C H. Chemotherapeutische Möglichkeiten bei metastasiertem kolorektalen Karzinom.  Dtsch Ärzteblatt. 2003;  100 705-714
    PubMedGoogle Scholar
  • 24 Rothenberg M L, Meropol N J, Poplin E A, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.  J Clin Oncol. 2001;  19 3801-3807
    PubMedGoogle Scholar
  • 25 Sargent D J, Niedzwiecki D, O'Connell M J, Schilsky R L. Recommendation for caution wirh irinotecan, fluorouracil, and leucovorin for colorectal cancer.  N Engl J Med. 2001;  345 144-145
    CrossrefPubMedGoogle Scholar
  • 26 Van Cutsem E, Dooillard J Y, Köhne C H. Toxicity of irinotecan in patients with colorectal cancer.  N Engl J Med. 2001;  345 1351-1352
    CrossrefPubMedGoogle Scholar
  • 27 Cunningham D, Pyrhonen S, James R. et al . Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.  Lancet. 1998;  352 1413-1418
    CrossrefPubMedGoogle Scholar
  • 28 Rougier P, Van Cutsem E, Bajetta E. et al . Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.  Lancet. 1998;  352 1407-1412
    CrossrefPubMedGoogle Scholar
  • 29 Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum Y M. Irinotecan in the treatment of colorectal cancer: clinical overview.  J Clin Oncol. 2001;  19 1501-1518
    PubMedGoogle Scholar
  • 30 Fuchs C S, Moore M R, Harker G. et al . Phase-III-comparison of two irinotecan dosing regimens in second-line therapy of metasatic colorectal cancer.  J Clin Oncol. 2003;  21 807-814
    CrossrefPubMedGoogle Scholar
  • 31 André T, Bensmaine M A, Louvet C. et al . Multicenter phase-II-study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.  J Clin Oncol. 1999;  17 3560-3568
    PubMedGoogle Scholar
  • 32 Bertheault-Cvitkovic F, Jami A, Ithzaki M. et al . Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.  J Clin Oncol. 1996;  14 2950-2958
    PubMedGoogle Scholar
  • 33 de Gramont A, Vignoud J, Tournigand C. et al . Oxaliplatin with high- dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer.  Eur J Cancer. 1997;  33 214-219
    CrossrefPubMedGoogle Scholar
  • 34 Diaz-Rubio E, Sastre J, Zaniboni A. et al . Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.  Ann Oncol. 1998;  9 105-108
    PubMedGoogle Scholar
  • 35 Levi F, Perpoint B, Garufi C. et al . Oxaliplatin activity against metastatic colorectal cancer. A phase-II-study of 5-day continuous venous infusion at circadian rhythm modulated rate.  Eur J Cancer. 1993;  29 1280-1284
    PubMedGoogle Scholar
  • 36 Machover D, Diaz-Rubio E, de Gramont A. et al . Two consecutive phase-II-studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.  Ann Oncol. 1996;  7 95-98
    PubMedGoogle Scholar
  • 37 Maindrault-Goebel F, Louvet C, André T. et al . Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.  Eur J Cancer. 1999;  35 1338-1342
    PubMedGoogle Scholar
  • 38 Scheithauer W, Kornek G V, Raderer M. et al . Randomized multicenter phase-II-trial of two different schedules of Capecitabine plus Oxaliplatin as first-line treatment in advanced colorectal cancer.  J Clin Oncol. 2003;  21 1307-1312
    CrossrefPubMedGoogle Scholar
  • 39 Lutz M P, Schöffski P, Folbrecht G. et al . A phase-I/II-study of cetuximab plus irinotecan (CPT-11) and infusional 5-FU7folinic acid in the treatment of metastatic colorectal cancer (MCRC) expressing the epidermal growth factor receptor.  Ann Oncol. 2003;  13 (Suppl 5) 73
    PubMedGoogle Scholar
  • 40 Maughan T S, James R D, Kerr D J. et al . Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicenter randomized trial.  Lancet. 2003;  361 457-464
    CrossrefPubMedGoogle Scholar
  • 41 Michael M, Zalcberg J R. The optimal 5-fluorouracil regimen for the adjuvant therapy of colon cancer: where to from here?.  Ann Oncol. 2000;  11 915-918
    CrossrefPubMedGoogle Scholar
  • 42 Porschen R, Bermann A, Loffler T. et al . Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.  J Clin Oncol. 1998;  19 1787-1794
    PubMedGoogle Scholar
  • 43 QUASAR Collaborative Group . Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial.  Lancet. 2000;  355 1588-1596
    CrossrefPubMedGoogle Scholar
  • 44 André T, Colin P, Louvet C. et al . Semimonthly versus monthly regimen of flourouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trail.  J Clin Oncol. 2003;  21 2896-2903
    CrossrefPubMedGoogle Scholar
  • 45 Scheithauer W, Mc Kendrick J, Begbie S. et al . Oral capecitabine as an alternative to i. v. 5-flourouracil-based adjuvant therapy for colon cancer: safety results of a randomized phase-III-trial.  Ann Oncol. 2003;  14 1735-1743
    CrossrefPubMedGoogle Scholar
  • 46 Köhne C H, Grothey A, Bokemeyer C, Bontke N, Aapro M. Chemotherapy in elderly patients with colorectal cancer.  Ann Oncol. 2001;  12 435-442
    CrossrefPubMedGoogle Scholar
  • 47 Sargent D J, Goldberg R M, Jacobson S D. et al . A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.  N Engl J Med. 2001;  345 1091-1097
    CrossrefPubMedGoogle Scholar
  • 48 Giacchetti S, Itzhaki M, Gruia G. et al . Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.  Ann Oncol. 1999;  10 663-669
    CrossrefPubMedGoogle Scholar
  • 49 Fong Y, Fortner J, Sun R L, Brennan M F, Blumgart L H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1 001 consecutive cases.  Ann Surg. 1999;  230 309-318
    CrossrefPubMedGoogle Scholar
  • 50 Lorenz M, Muller H H, Schramm H. et al . Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases.  Ann Surg. 1998;  228 756-762
    CrossrefPubMedGoogle Scholar
  • 51 Kemeny M M, Adak S, Gray B. et al . Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study.  J Clin Oncol. 2002;  20 1499-1505
    CrossrefPubMedGoogle Scholar

PD Dr. Thomas Seufferlein

Abt. Innere Medizin I · Universitätsklinikum Ulm

Robert Koch-Str. 8

89081 Ulm

Phone: 07 31-5 00-0

Fax: 07 31-5 00-2 43 02

Email: thomas.seufferlein@medizin.uni-ulm.de

      >